United Therapeutics reported unexpected positive results from a Phase 3 trial of its inhaled treprostinil formulation, Tyvaso, in idiopathic pulmonary fibrosis (IPF). The study met its primary endpoint demonstrating significant improvement in forced vital capacity over 52 weeks with consistent safety profiles. The success opens a large new market for Tyvaso, as IPF remains a challenging disease with limited treatment options. The company plans to submit for expanded regulatory approval as a result of these findings.